ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncogene
Главные авторы: Berns, Katrien, Caumanns, Joseph J., Hijmans, E. Marielle, Gennissen, Annemiek M. C., Severson, Tesa M., Evers, Bastiaan, Wisman, G. Bea A., Jan Meersma, Gert, Lieftink, Cor, Beijersbergen, Roderick L., Itamochi, Hiroaki, van der Zee, Ate G. J., de Jong, Steven, Bernards, René
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095834/
https://ncbi.nlm.nih.gov/pubmed/29760405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0300-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы